Drugs

Latest FDA Warning Letters

FDA has posted its latest batch of Warning Letters. They can be accessed by clicking on the link following each letter.

Blaine Labs, Santa Fe Springs, CA (5/5): FDA inspected the firm 9/2019 and cited significant GMP violations for finished pharmaceuticals. For example, the company failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications. The company also failed to establish adequate written procedures for production and process controls designed to assure that the drug products it manufactures have the identity, strength, quality, and purity they purport or are represented to possess. To view the letter, click here.

Lymol Medical, Woburn, MA (4/7): FDA inspected the company in February and cited GMP deficiencies with its Elite X Class Rigid Bronchoscope System and Premier S Class Silicone Stents. For example, Lymol failed to validate the manual cleaning processes, sterilization processes, and storage conditions for its devices. The company also failed to establish and maintain procedures for identification, documentation, validation or where appropriate verification, review, and approval of design changes before implantation. To view the letter, click here.

International Trading Pharm Lab, Paterson, NJ (4/24): FDA inspected the firm and cited GMP deficiencies for active pharmaceutical ingredients (API). For example, the firm’s quality unit failed to ensure that drugs are appropriately tested and the results are reported. Additionally, it failed to establish and follow written procedures for investigating critical deviations or the failure of API batches to meet specifications. To view the letter, click here.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome